Skip to main content

Table 2 Data analysed for correlation with overall survival

From: Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parameters

DC parameters T cell parameters
DC (HLA-DR+ lin-) % of PBMC CD8 + % of CD3+
BDCA-1+ DC % of total PBMC Ki67+% of CD8 T cells
BDCA-2+ DC % of total PBMC ICOS+% of CD8 T cells
BDCA-3+ DC % of total PBMC Teff (HLA-DR+CD38+) % of CD8 T cells
BDCA-1+ % of DC CD3+% of lymphocytes
BDCA-2+ % of DC CD4+% of CD3+
BDCA-3+ % of DC Ki67+% of CD4 T cells
BDCA-1+:BDCA-2+ ratio ICOS+% of CD4 T cells
BDCA-1+:BDCA-3+ ratio Treg+% of CD4 T cells
BDCA-2+:BDCA-3+ ratio ki67 + % of Treg (CD25+CD127loFoxp3+)
BDCA-1+ DC CD40 MFI ICOS + % of Treg (CD25+CD127loFoxp3+)
BDCA-1+ DC HLA-DR MFI  
BDCA-2+ DC CD40 MFI  
BDCA-2+ DC HLA-DR MFI  
BDCA-3+ DC CD40 MFI  
BDCA-3+ DC HLA-DR MFI  
  1. List of parameters undergoing exploratory analysis for correlation with OS. Flow cytometry data was used to group patients above or below the median for each parameter, and repeated using data from each sample collection time point from baseline through to Cycle 3 Day 8